ライフサイエンスコーパス: ADC

1 ADC and (Cit + Spm + Cr)/Cho ratio showed positive corre

2 ADC and K were concordant for these various outcomes in

3 ADC and K were highly correlated (r = -0.82; P < .001).

4 ADC and T2 together produced the highest AUC of 0.83 for

5 ADC and tract length and volume have an earlier and smal

6 ADC map evaluation improves diagnostic performance in re

7 ADC measurements were carried out by two radiologists wh

8 ADC peaks 2 years earlier than tract volume (girls at 9.

9 ADC proved to be a positive predictor of (18)F-FDG in th

10 ADC ratio (mean posttreatment ADC/mean pretreatment ADC)

11 ADC significantly reduced the in vivo uptake of all 3 mA

12 ADC values were measured in intact bone marrow and major

13 ADC was also related to an increase in ECV (R(2) = 0.210

14 ADC, perfusion-related diffusion fraction (f), slow diff

15 ADCs also induced immunologic memory.

16 ADCs greater than 0.548 x 10(-3) mm(2)/sec showed 100% s

17 ADCs had greater antitumor activity in immunocompetent v

18 ADCs targeting HER2 were prepared and demonstrated to be

19 ADCs were generated by S239C mutation to give a ratio of

20 ADCs were measured by two radiologists using three circu

21 cquired and analyzed by one dimensional (1D) ADC, T1, and T2 distributions as well as by paired two-d

22 d sacituzumab govitecan (IMMU-132), a Trop-2 ADC, for the targeting of SN-38.

23 e PPS(+) patients displayed a lower absolute ADC difference than did the PPS(-) patients.

24 al studies show SGN-CD19B is a highly active ADC, which releases a DNA cross-linking agent rather tha

25 ) obtained with monoexponential fit (ADCME), ADC obtained with stretched exponential modeling (ADCSE)

26 Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) are the two pred

27 age switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion o

28 Also, ADCs with a nonprotease-cleavable enantiomer, the VC(R)

29 An ADC typically consists of a small molecule or peptide-ba

30 n pharmacokinetics and tumor targeting of an ADC, Lx-DFO was conjugated to the HER2 mAb trastuzumab,

31 (T2W) image 'gold-standard' volume and on an ADC image volume derived from DW images acquired over th

32 e (vs normal) MR imaging pattern, whereas an ADC greater than 0.597 x 10(-3) mm(2)/sec showed 96% sen

33 ion of lymphoid and myeloid cells by ADC and ADC/immuno-oncology combinations.

34 termining CR from pre- and post-CRT ADCs and ADC change.

35 Post-CRT and ADC change measurements achieved negative predictive val

36 e complementary information of (18)F-FDG and ADC longitudinal measurements in xenograft tumors allows

37 DG PET images, postgadolinium MR images, and ADC MR images were registered to baseline fluid attenuat

38 ive associations were noted between LVMI and ADC (Spearman = 0.450, p < 0.05) and between LVMI and EC

39 and nuclei, (Cit + Spm + Cr)/Cho ratio, and ADC were significantly different (P < .001) between beni

40 With a synchronous change in T2 and ADC signals, microglial activation peaked on day 3 in th

41 T1, T2, and ADC from cancer (mean, 1628 msec +/- 344, 73 msec +/- 27

42 ic regression was used to assess T1, T2, and ADC in the differentiation of (a) cancer versus NPZ, (b)

43 T1, T2, and ADC were recorded for each region.

44 Conclusion Lobar ventilation and ADC values obtained from hyperpolarized (129)Xe MR imagi

45 eneous glycoforms of produced antibodies and ADCs, compatibility with diverse natural and non-natural

46 Native mAbs and ADCs were characterized, after conjugation to a DFO chel

47 n platform for the preparation of anticancer ADCs.

48 Dual-auristatin ADCs imparted activity in cell line and xenograft models

49 lts Percentage ventilated volume and average ADC at lobar (129)Xe MR imaging showed correlation with

50 The average ADC at whole-lung (129)Xe MR imaging showed moderate cor

51 based ADCs, but not with a duocarmycin-based ADC, significantly impaired tumor growth and prolonged m

52 rial therapies with PBD- and tubulysin-based ADC and immuno-oncology drugs that may increase clinical

53 cle, treatment with either of the MMAE-based ADCs, but not with a duocarmycin-based ADC, significantl

54 based microtubule inhibitor, the biparatopic ADC demonstrates superior anti-tumor activity over ado-t

55 erences between the right and left branches (ADC, thickness) were compared between the two groups.

56 omodulation of lymphoid and myeloid cells by ADC and ADC/immuno-oncology combinations.

57 D PRESSMRS sequences, and we also calculated ADC values and Cho Cr/Cit MRS ratios for all patients.

58 PAFs were 2.6% for AIDS-defining cancers (ADCs, including non-Hodgkin lymphoma, 2.0% of deaths) an

59 in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses).

60 rast, pyrrolobenzodiazepine-conjugated CD276 ADCs killed both cancer cells and tumor vasculature, era

61 In preclinical studies CD276 ADCs armed with a conventional MMAE warhead destroyed CD

62 l fluorescence ratios quantified single-cell ADC uptake and metabolism and confirmed that the in vivo

63 Antibody directed chemotherapy (ADC) takes advantage of the selectivity of the monoclona

64 Maps of apparent diffusion coefficient (ADC) and diffusional kurtosis (K) were derived by using

65 and measured apparent diffusion coefficient (ADC) and tract length and volume.

66 atability of apparent diffusion coefficient (ADC) estimates in extracranial soft-tissue diffusion-wei

67 baseline MRI apparent diffusion coefficient (ADC) histogram metrics, progression-free survival (PFS),

68 analysis of apparent diffusion coefficient (ADC) in the diagnosis of incomplete testicular torsion.

69 Apparent Diffusion Coefficient (ADC) is a potential quantitative imaging biomarker for t

70 and standard apparent diffusion coefficient (ADC) mapping for multiparametric characterization of pro

71 intensity on apparent diffusion coefficient (ADC) maps were significantly associated with an incomple

72 ging-derived apparent diffusion coefficient (ADC) maps with fat-saturated (FS) proton density (PD)-we

73 itioning for apparent diffusion coefficient (ADC) measurements on the assessment of complete response

74 features of apparent diffusion coefficient (ADC) MR images are to changes in five parameters related

75 l zone (PZ): apparent diffusion coefficient (ADC) obtained with monoexponential fit (ADCME), ADC obta

76 The apparent diffusion coefficient (ADC) of (3)He at 1 second was significantly higher in pa

77 nd increased apparent diffusion coefficient (ADC) signal.

78 The apparent diffusion coefficient (ADC) value of the thyroid gland was calculated and corre

79 ng (DWI) and apparent diffusion coefficient (ADC) values at 3 Tesla in characterizing sinonasal masse

80 tilation and apparent diffusion coefficient (ADC) values obtained with hyperpolarized xenon 129 ((129

81 on times and apparent diffusion coefficient (ADC) values of the liver and focal liver lesions on a 1.

82 TSC and apparent diffusion coefficient (ADC) were calculated and correlated for healthy glandula

83 (FA) and the apparent diffusion coefficient (ADC) were calculated, as were T2 relaxation time and pro

84 gions of low apparent diffusion coefficient (ADC) with high relative cerebral blood volume (rCBV) rep

85 s and median apparent diffusion coefficient (ADC) with response to treatment were assessed by using t

86 nces in the apparent diffusion coefficients (ADCs) and the thickness of the right and left branches o

87 valuate the apparent diffusion coefficients (ADCs) of magnetic resonance (MR) imaging patterns in the

88 termined by apparent diffusion coefficients (ADCs) on MRI were analyzed and compared with urinalysis,

89 The apparent diffusion coefficients (ADCs) were evaluated for two different b values (b=600 s

90 Apparent diffusion coefficients (ADCs) were obtained by using two different methods.

91 ay analysis of variance were used to compare ADCs between patient subsets and control subjects, and a

92 hitney and chi(2) tests were used to compare ADCs between the two cohorts, and chi(2) automatic inter

93 Conclusion ADC and K were highly correlated, had similar diagnostic

94 Conclusion ADC is a robust imaging metric with excellent repeatabil

95 Conclusion ADC maps are more sensitive than corresponding FS PD-wei

96 Conclusion ADCs of MR imaging patterns in patients with MM differ s

97 BD)-based anti-CD19 antibody drug conjugate (ADC) being investigated for treatment of B-cell malignan

98 e generated a novel antibody-drug conjugate (ADC) enfortumab vedotin comprising the human anti-nectin

99 nsine (T-DM1) is an antibody-drug conjugate (ADC) that was approved recently to treat HER2(+) breast

100 AY 1187982, a novel antibody-drug conjugate (ADC).

101 Antibody-drug conjugates (ADC) are designed to selectively bind to tumor antigens

102 Current antibody-drug conjugates (ADC) have made advances in engineering the antibody, lin

103 ple in the form of antibody-drug conjugates (ADC).

104 used to synthesize antibody-drug conjugates (ADC).

105 apping analyses of antibody-drug conjugates (ADCs) and their parent antibodies.

106 Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which h

107 Antibody-drug conjugates (ADCs) are among the most promising empowered biologics f

108 Antibody-drug conjugates (ADCs) are an important class of therapeutic molecule cur

109 ion of homogeneous antibody-drug conjugates (ADCs) containing multiple payloads has been developed.

110 the development of antibody-drug conjugates (ADCs) for cancer chemotherapy.

111 Therefore, antibody-drug conjugates (ADCs) have been developed to specifically deliver highly

112 ay be a target for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

113 r vasculature with antibody-drug conjugates (ADCs) is a promising anti-cancer strategy that in order

114 Antibody-drug conjugates (ADCs) of defined structure hold great promise for cancer

115 Antibody-drug conjugates (ADCs) offer increased efficacy and reduced toxicity comp

116 roduce homogeneous antibody-drug conjugates (ADCs) rely on mutations or inefficient conjugation chemi

117 yields homogeneous antibody drug conjugates (ADCs) that can be optimized for conjugation site, drug t

118 tibodies to create antibody-drug conjugates (ADCs), a number of which are now in clinical trials, wit

119 Preparation of antibody-drug conjugates (ADCs), an emerging novel class of highly targeted biolog

120 em as payloads for antibody drug conjugates (ADCs), while a number of them revealed impressive activi

121 m, and constructed antibody-drug conjugates (ADCs).

122 sis as compared to antibody-drug conjugates (ADCs).

123 iate 19 for use in antibody-drug conjugates (ADCs).

124 first PBD dimers, and then to PBD-containing ADCs, and explores both structure-activity relationships

125 ters employing analog-to-digital converters (ADCs) and electron multipliers, the statistical distribu

126 nce in determining CR from pre- and post-CRT ADCs and ADC change.

127 Post-CRT ADCs and values of ADC changes accurately identify nonco

128 red saline) to 20 and 29 d for DAR2 and DAR4 ADC, respectively.

129 ho-planar diffusion-weighted imaging-derived ADC mapping.

130 the therapeutic efficacy of the 4 different ADCs was assessed in mice with LS174T-PSMA tumors.

131 butions as well as by paired two-dimensional ADC-T1, ADC-T2 and T1-T2 distributions.

132 Corresponding with this, proximal and distal ADCs were highest in patients with sDPN compared with pa

133 th DKI modeling (ADCDKI), kurtosis with DKI, ADC obtained with DTI (ADCDTI), and fractional anisotrop

134 method for construction of potent dual-drug ADCs and demonstrates how delivery of multiple cytotoxic

135 lpha) obtained at stretched exponential DWI, ADC obtained with DKI modeling (ADCDKI), kurtosis with D

136 d images/apparent diffusion coefficient (DWI/ADC) images of 86 lymph nodes from 31 cancer patients we

137 The most efficacious ADC showed complete tumor regression and 10/10 tumor fre

138 or the preparation of stable and efficacious ADCs.

139 vivo potency for producing more efficacious ADCs.

140 C development, with the potential to enhance ADC in vivo potency for producing more efficacious ADCs.

141 -disrupting cytotoxic drug auristatin (FGFR2-ADC).

142 cated that the toxophore metabolite of FGFR2-ADC was enriched more than 30-fold in tumors compared wi

143 urve was significantly higher (P = .002) for ADC (0.921) than for K (0.902) for benign versus maligna

144 ly robust, enabling the use of crude DVD for ADC preparation.

145 in PCa, it represents a promising target for ADC-based therapies.

146 d the intraclass correlation coefficient for ADCs was 0.788 (P < .001).

147 the strategies for their use as payloads for ADCs.

148 R-3 and KPL-4 (7 inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 mug/mL (7

149 In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was observed with tumor stasis at 0.5-

150 -rCBV regions of interest (ROIs) (hereafter, ADC-rCBV ROIs) were generated in contrast-enhancing and

151 showing absence of late enhancement and high ADC ratio after NST are associated with pCR.

152 al angiofibroma (JNA) showed distinctly high ADC values, while meningioma was the only benign lesion

153 n vivo properties of a series of homogeneous ADCs with a conserved site of conjugation, a monodispers

154 tibody-based tumor delivery may help improve ADC engineering for better tumor targeting and reduced s

155 at 3:1 and 8:1 ratios dramatically improved ADC tumor penetration and resulted in twice the improvem

156 e and enables high drug loading for improved ADC potency.

157 iple cytotoxic warheads can lead to improved ADC activities.

158 in the interpretation of measured changes in ADC using a data-driven model that describes sources of

159 rug-linker design as a critical parameter in ADC development, with the potential to enhance ADC in vi

160 Cho/NAA ratio in ADC-rCBV ROIs was compared with that in control regions

161 e or plasma clearance, plays a major role in ADC efficacy.Significance: This study shows how lowering

162 The absolute difference in ADCs (right branch - left branch) was significantly diff

163 There were significant differences in ADCs between diffuse and normal (P < .001), diffuse and

164 Conjugation resulted in ADCs with unimpaired mAb-binding characteristics, DAR in

165 rtainty from statistical error on individual ADC measurements.

166 +/- 2.6 MBq) with 25 mug of (111)In-labeled ADCs were performed on BALB/c nude mice with subcutaneou

167 )/sec or less (hazard ratio [HR] = 8.3), low ADC signal intensity (HR = 7.3), high signal intensity a

168 Overlapping low-ADC and high-rCBV regions of interest (ROIs) (hereafter,

169 nerable to glycolytic inhibition, while lung ADC exhibits significant glucose independence.

170 diffusion-weighted imaging, and bone marrow ADCs were calculated.

171 Comparisons of minimum, mean, and maximum ADC values in testicles were performed with the Wilcoxon

172 Mean ADC and K were obtained from volumes of interest (VOIs)

173 Mean ADC ratio significantly increased when pCR was achieved

174 A mean ADC of 0.0014 m(2)/sec or less (hazard ratio [HR] = 8.3)

175 assess the repeatability of median and mean ADC estimates.

176 were quantified as percentage change in mean ADC (test vs. re-test) and then standardised against an

177 e images and quantitative assessment of mean ADC values.

178 The mean ADC value of benign lesions was 1.948+/-0.459x10(-3) mm(

179 The mean ADC value of liver lesions was lower on enhanced than on

180 The mean ADC value of the thyroid gland in Graves' disease was 2.

181 The mean ADC value of the thyroid gland in patients positively co

182 Results Mean ADCs +/- standard deviation in patients with MM for the

183 decreases in volume and increases in median ADC of bone metastases assessed with whole-body DWI can

184 Increases in median ADC were associated with increased odds of response (odd

185 Results The median ADC of postoperative abscesses was 1.34 x 10(-3) mm(2)/s

186 ich was significantly higher than the median ADC of spontaneous abscesses, 0.68 x 10(-3) mm(2)/sec (i

187 potent antitumor responses while minimizing ADC-induced toxicity.

188 Minimum ADC values can be used as an auxiliary method in the dia

189 Comparing minimum ADC values between the affected and non-affected testicl

190 In the torsion group, minimum ADC values for left testicles were significantly lower t

191 Unlike the VC-MMAE ADCs, the VC(S)-PBD ADC is at least 20-fold more cytotox

192 erest for each tumor were plotted against MR ADC values.

193 Further, the level of PET and MR ADC correlation was significantly positively associated

194 Conclusion:(18)F-FDG PET and MR ADC histogram metrics in pediatric DIPG demonstrate diff

195 Correlation between PET and MR ADC histogram metrics was evaluated.

196 adolinium MR images and (18)F-FDG PET and MR ADC histograms were generated.

197 PET and MR ADC pixel values were negatively correlated using the Pe

198 en a negative correlation between PET and MR ADC pixel values.

199 Higher MR ADC postgadolinium kurtosis tended toward shorter PFS (h

200 a significant association between higher MR ADC postgadolinium skewness and shorter PFS (hazard rati

201 , suggesting that a higher level of negative ADC-PET correlation leads to less favorable PFS.

202 nal progression from normal aging to AD (NIA ADC, Cochran-Armitage trend test, p = 1.5 x 10-10), and

203 ute on Aging Alzheimer's Disease Center [NIA ADC], and Alzheimer's Disease Neuroimaging Initiative [A

204 and was associated with neuropathology (NIA ADC, Braak stage of neurofibrillary tangles, p = 3.9 x 1

205 hazard ratio per 0.01 increase in normalized ADC, 0.91-0.94; P < .04).

206 Observed ADC is then standardised against this estimation of unce

207 The action of ADC in vivo can be hard to predict based on target expre

208 Conclusion Volumetric analysis of ADC-rCBV ROIs in nonenhancing regions of GBM can be used

209 le exceptions, broad clinical application of ADC remains elusive; major hurdles include the instabili

210 To highlight the benefits of ADC dual drug delivery, this strategy was applied to the

211 early, thorough in vivo characterization of ADC candidates.

212 trates that the intratumoral distribution of ADC, independent of payload dose or plasma clearance, pl

213 mab emtansine (T-DM1) to study the impact of ADC tumor distribution on efficacy.

214 Increased levels of ADC were associated with reduced peak systolic and early

215 The repeatability of ADC estimates from small, medium, and large tumors and h

216 med to obtain sensitivity and specificity of ADC values in association with delivery within 7 days.

217 Post-CRT ADCs and values of ADC changes accurately identify noncomplete responders.

218 iated with PFS; tumors with higher values of ADC-PET correlation had more favorable PFS (hazard ratio

219 mutation status, the proportional volume of ADC-rCBV ROIs in nonenhancing regions significantly cont

220 of CD8(+) T cells abrogated the activity of ADCs when used alone or in combination with a PD-L1 anti

221 Combinations of ADCs with immuno-oncology drugs, including PD-1 or PD-L1

222 y used for the site-specific construction of ADCs and appraises their merits and disadvantages.

223 Good correlation of ADCs obtained with the single-value method and those obt

224 erved in some cases with suboptimal doses of ADCs, potentially providing an approach to achieve poten

225 us intratumoral distribution and efficacy of ADCs is poorly understood.

226 A knockdown had no effect on the efficacy of ADCs with VC(S) linkers armed with a monomethyl auristat

227 emotherapies, combining the best features of ADCs with those of nanoparticle-based therapeutics.

228 nlikely to increase the therapeutic index of ADCs and that resistance based on linker processing is i

229 s strategy was applied to the preparation of ADCs containing two classes of auristatin drug-linkers t

230 (ROC) curve was drawn to determine a cut-off ADC value for the differentiation between benign and mal

231 When a cut-off ADC value of 1.791x10(-3) mm(2)/s was used, sensitivity

232 tly more patients showed at least one BML on ADC maps (98%, 95 of 97 patients) than on FS PD-weighted

233 175 regions) were identified consistently on ADC maps.

234 Only 58% of the affected regions detected on ADC maps (170 of 293 regions) were identified on FS PD-w

235 es more detailed and accurate information on ADC biotransformations in vivo, enabling analysis of low

236 or BML was approximately two times larger on ADC maps (81 cm(3)) than on FS PD-weighted TSE images (3

237 leavable valine-citrulline [VC(S)] linker on ADC efficacy.

238 Because other ADC may use the same internalization-degradation pathway

239 r than the level of drug required with other ADC payloads.

240 ich has improved potency compared with other ADCs.

241 st 20-fold more cytotoxic than the VC(R)-PBD ADC.

242 Unlike the VC-MMAE ADCs, the VC(S)-PBD ADC is at least 20-fold more cytotoxic than the VC(R)-PB

243 In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 model

244 WTV measurement of percentage ADC change provides the best results.

245 ean, median, 75th, 90th, and 95th percentile ADCs (ADCmean, ADC50, ADC75, ADC90, and ADC95, respectiv

246 ADC ratio (mean posttreatment ADC/mean pretreatment ADC) was calculated.

247 ug-linker design was further used to prepare ADCs with different drug loadings of 4, 6 and 8 drugs pe

248 io (mean posttreatment ADC/mean pretreatment ADC) was calculated.

249 The site-specifically conjugated anti-PSMA ADCs D2B-DAR2-MMAE and D2B-DAR4-MMAE efficiently targete

250 nomethyl auristatin E (MMAE)-based anti-PSMA ADCs with drug-to-antibody ratios (DARs) of 2 and 4.

251 For all time points the relative ADC increase (DeltaADC) compared to the ADC pre-CRT was

252 Results ADC and K showed significant differences for benign vers

253 Results ADC-rCBV ROIs within contrast-enhancing and nonenhancing

254 nts; among patients with discordant results, ADC showed better performance than K for GS </= 3 + 4 ve

255 DFT and SCS-ADC(2) calculations showed that contaminant-contaminant

256 form was used to prepare potent and specific ADCs targeting CD138 and CD79B, two clinically establish

257 present a strategy to produce site-specific ADCs using a highly reactive natural buried lysine embed

258 low-dose, labile, and complex site-specific ADCs with linker-drug conjugated in the Fab region.

259 Conclusion Cervical subglandular ADC at MR imaging is associated with impending preterm b

260 The model combining the IHC subtype, ADC ratio, and late enhancement had the highest associat

261 as well as by paired two-dimensional ADC-T1, ADC-T2 and T1-T2 distributions.

262 CD30-targeting ADC delivering membrane permeable MMAE or pyrrolobenzodi

263 We concluded that ADC values of the thyroid gland can be used to different

264 The ADC values of intact bone marrow and BMLs did not overla

265 of fibrosis and the relationship between the ADC value and systolic strain in hypertensive patients w

266 Different methods for constructing the ADC maps did not have an impact on any texture feature.

267 d pre-processing: noise, resolution, how the ADC map is constructed, the choice of quantization metho

268 There was a significant difference in the ADC value of the thyroid gland between patients and the

269 statistically significant difference in the ADC value, thickness or the absolute difference in thick

270 There was a significant difference in the ADC values between Graves' disease and painless thyroidi

271 ature of the lysine conjugation process, the ADC molecules are heterogeneous, containing a range of s

272 of the H3K27 methyltransferase EZH2 than the ADC lesions, but there is a clear lack of the essential

273 No neutralizing antibodies to the ADC or antibody were detected, despite repeated cycles d

274 tive ADC increase (DeltaADC) compared to the ADC pre-CRT was higher in GR (P < 0.001).

275 When the ADC value of 1.45x10(-3) mm(2)/sec was used as a thresho

276 Regardless of whether the ADC was acquired through single-ROI (0.10 +/- 0.08 vs 0.

277 d receptor as well as its interplay with the ADC can have drastic effects on cell apoptosis versus su

278 The ADCs, which differed only in the relative position of ce

279 detection analysis was used to classify the ADCs into categories according to the cohorts.

280 the position of a discrete polymer unit, the ADCs showed comparable in vitro potencies, but the in vi

281 m provides the means to generate therapeutic ADCs inaccessible by other methods that are efficient in

282 ne system to the antitumor activity of these ADCs.

283 This ADC should be studied further in this disease and in oth

284 le myeloma (MM) and to determine a threshold ADC that may help distinguish a diffuse from a normal pa

285 analysis was performed to identify threshold ADCs.

286 d intracellular targets are more critical to ADC efficacy.

287 l functionality might overcome resistance to ADC-based therapies and improve their effectiveness.

288 Mortality rates attributable to ADCs and NADCs were highest for PWHIV with CD4 counts <1

289 and xenograft models that are refractory to ADCs comprised of the individual auristatin components.

290 nal cysteine unmasking are not restricted to ADCs and can be broadly utilized for site-specific prote

291 Conclusion Tumor ADCs are highly dependent on the ROI positioning method

292 e extracted and normalized to the mean urine ADC (nADCmean, nADC50, nADC75, nADC90, and nADC95, respe

293 the peripheral zone (AUC, 0.85; P = .010 vs ADC alone) and whole gland (AUC, 0.77; P = .043 vs ADC a

294 one) and whole gland (AUC, 0.77; P = .043 vs ADC alone).

295 he Levene test was used to determine whether ADC repeatability differed between studies.

296 he Levene test was used to determine whether ADC repeatability differed between these groups.

297 and demonstrates an inverse correlation with ADC.

298 tate precession-based MR fingerprinting with ADC mapping.

299 the use of novel modalities such as MRI with ADC sequences and PET.

300 border but did not change synchronously with ADC signals.

301 Sacin correlated strongly with ADCs at 1 second (R = 0.65, P < .001) but weakly with AD

302 second (R = 0.65, P < .001) but weakly with ADCs at 13 ms (R = 0.38, P < .05).